Literature DB >> 3311109

Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.

W D Miner1, G J Sanger, D H Turner.   

Abstract

The involvement of 5-hydroxytryptamine (5-HT) 5-HT3 receptors in the mechanisms of severe emesis evoked by cytotoxic drugs or by total body irradiation have been studied in ferrets. Anti-emetic compounds tested were domperidone (a dopamine antagonist), metoclopramide (a gastric motility stimulant and dopamine antagonist at conventional doses, a 5-HT3 receptor antagonist at higher doses) and BRL 24924 (a potent gastric motility stimulant and a 5-HT3 receptor antagonist). Domperidone or metoclopramide prevented apomorphine-evoked emesis, whereas BRL 24924 did not. Similar doses of domperidone did not prevent emesis evoked by cis-platin or by total body irradiation, whereas metoclopramide or BRL 24924 greatly reduced or prevented these types of emesis. Metoclopramide and BRL 24924 also prevented emesis evoked by a combination of doxorubicin and cyclophosphamide. These results are discussed in terms of a fundamental role for 5-HT3 receptors in the mechanisms mediating severely emetogenic cancer treatment therapies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311109      PMCID: PMC2002136          DOI: 10.1038/bjc.1987.177

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  A pilot study of high-dose domperidone as an antiemetic in patients treated with cisplatin.

Authors:  M Tonato; F Roila; A del Favero; G Tognoni; M G Franzosi; S Pampallona
Journal:  Eur J Cancer Clin Oncol       Date:  1985-07

2.  Cisplatin-induced emesis in the Ferret: a new animal model.

Authors:  A P Florczyk; J E Schurig; W T Bradner
Journal:  Cancer Treat Rep       Date:  1982-01

3.  Altered gastric emptying and prevention of radiation-induced vomiting in dogs.

Authors:  A Dubois; J P Jacobus; M P Grissom; R R Eng; J J Conklin
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

4.  Gastric and small intestinal myoelectric dysrhythmia associated with chronic intractable nausea and vomiting.

Authors:  C H You; W Y Chey; K Y Lee; R Menguy; A Bortoff
Journal:  Ann Intern Med       Date:  1981-10       Impact factor: 25.391

5.  Effect of ionizing radiation on gastric secretion and gastric motility in monkeys.

Authors:  E Danquechin Dorval; G P Mueller; R R Eng; A Durakovic; J J Conklin; A Dubois
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

6.  Neuronal 5-HT receptors in the periphery.

Authors:  J R Fozard
Journal:  Neuropharmacology       Date:  1984-12       Impact factor: 5.250

Review 7.  Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors:  R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

8.  Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility.

Authors:  R S Alphin; A G Proakis; C A Leonard; W L Smith; W N Dannenburg; W J Kinnier; D N Johnson; L F Sancilio; J W Ward
Journal:  Dig Dis Sci       Date:  1986-05       Impact factor: 3.199

Review 9.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

10.  Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis.

Authors:  R Saller; D Hellenbrecht
Journal:  Cancer Treat Rep       Date:  1985-11
View more
  30 in total

1.  Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG.

Authors:  T J Leigh; C G Link; G L Fell
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 2.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

3.  Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.

Authors:  A Hamik; S J Peroutka
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.

Authors:  E A Perez
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 5.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 6.  Chemotherapy-induced nausea and vomiting: optimizing prevention and management.

Authors:  Kamakshi V Rao; Aimee Faso
Journal:  Am Health Drug Benefits       Date:  2012-07

7.  Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron.

Authors:  C P Schröder; W T van der Graaf; I P Kema; A Groenewegen; D T Sleijfer; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.

Authors: 
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties.

Authors:  D H Staniforth; M Pennick
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells.

Authors:  M I Sepúlveda; S C Lummis; I L Martin
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.